Kevan Herold, MD

Kevan Herold, MD, is an endocrinologist who treats adult and child patients with type 1 and type 2 diabetes, diabetes that occurs after therapies for cancer, and hypoglycemia (low blood glucose levels). 

Type 1 diabetes is an autoimmune disease that is often diagnosed in children and teens. The immune system mistakenly attacks healthy body tissues and destroys cells in the pancreas that produce insulin. 

Dr. Herold’s goal is to better understand the mechanisms for type 1 diabetes in order to develop new treatments for his patients. His research revolves around beta cell function. In type 1 diabetes, beta cells produce little or no insulin and are destroyed by T cells from the immune system. Dr. Herold and his lab also research autoimmune diabetes development in cancer patients. 

Recently, Dr. Herold was the principal investigator for a clinical trial that showed the effectiveness of teplizumab, a new drug that could delay type 1 diabetes development by two years. He is chair of NIDDK (National Institute of Diabetes and Digestive Diseases) TrialNet, an international network of type 1 diabetes researchers.  

Dr. Herold is C.N.H. Long Professor of Immunobiology and of Medicine (Endocrinology) at Yale School of Medicine.